Healthcare entity
Every one of those 2 sits in a single category, market-trends. 4D Medical is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 5.5 average consequence score is below the beat benchmark of 5.7 in the same window.
Last mentioned: Mar 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, market-trends. 4D Medical is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. The 5.5 average consequence score is below the beat benchmark of 5.7 in the same window. They are less corroborated than the beat average, carrying 3.5 original sources each against 3.9 for the same window. This profile follows 2 Healthcare stories mentioning CSL across the period from February 25, 2026 to March 2, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 108 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CSL. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.
Source: 0 Comments (au) · 0 Comments (au)
CSL is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
